IT-141 is under clinical development by Intezyne and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IT-141’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

IT-141 overview

IT-141 is under development for the treatment of solid tumor includes colorectal cancer and breast cancer. The therapeutic candidate is administered through intravenous route. The therapeutic candidate is an IVECT encapsulated SN-38 nanoparticle and active metabolite of irinotecan. It is a 7-ethyl-10-hydroxy camptothecin. The drug candidate is developed based on IVECT technology, which reduces the drug toxicity by securely encapsulating the active therapeutic agent in the proprietary IVECT micelle, a polymeric nanoparticle that minimizes drug exposure to healthy tissues. It acts by targeting topoisomerase I.

Intezyne overview

Intezyne is a biotechnology company that develops product candidates for the treatment of various cancer tumors. The company offers anti-cancer agents and IVECT method to improve cancer therapy. It provides compounds that are cellular or molecularly targeted or have tumor-specific release mechanisms. Intezyne’s pipeline products include IT-139, IT-141 and IT-147. The company’s IT-141 is a formulation of SN-38 encapsulated using its nanoparticle drug delivery platform. It has active preclinical research programs for delivery of DNA and siRNA, molecularly targeted drugs and orally delivered IVECT therapeutics. Intezyne is headquartered in Tampa, Florida, the US.

For a complete picture of IT-141’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.